CF
MRNA icon

Centaurus Financial’s Moderna MRNA Stock Holding History

Centaurus Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Hold
4,477
– – 0.01% 735
2026
Q1 		$227K Sell
4,477
-5,700
-56% -$266K 0.01% 779
2025
Q4 		$300K Sell
10,177
-6,007
-37% -$163K 0.01% 683
2025
Q3 		$418K Buy
16,184
+10,007
+162% +$279K 0.02% 574
2025
Q2 		$170K Sell
6,177
-35
-0.6% -$922 0.01% 776
2025
Q1 		$176K Sell
6,212
-75
-1% -$2.66K 0.01% 716
2024
Q4 		$261K Sell
6,287
-13
-0.2% -$621 0.02% 592
2024
Q3 		$421K Sell
6,300
-35
-0.6% -$3.21K 0.03% 447
2024
Q2 		$752K Sell
6,335
-608
-9% -$76.9K 0.05% 295
2024
Q1 		$740K Sell
6,943
-140
-2% -$14.1K 0.05% 295
2023
Q4 		$704K Buy
7,083
+214
+3% +$18K 0.05% 299
2023
Q3 		$709K Sell
6,869
-68
-1% -$7.58K 0.06% 293
2023
Q2 		$843K Sell
6,937
-1,555
-18% -$207K 0.07% 266
2023
Q1 		$1.3M Buy
8,492
+35
+0.4% +$5.77K 0.1% 219
2022
Q4 		$1.52M Sell
8,457
-403
-5% -$65.9K 0.14% 174
2022
Q3 		$1.05M Sell
8,860
-110
-1% -$16.7K 0.1% 231
2022
Q2 		$1.28M Sell
8,970
-374
-4% -$53.5K 0.13% 195
2022
Q1 		$1.61M Buy
9,344
+39
+0.4% +$6.57K 0.13% 193
2021
Q4 		$2.36M Sell
9,305
-606
-6% -$177K 0.18% 151
2021
Q3 		$3.81M Sell
9,911
-3,445
-26% -$1.27M 0.32% 72
2021
Q2 		$3.14M Buy
13,356
+6,918
+107% +$1.24M 0.26% 92
2021
Q1 		$843K Buy
6,438
+1,198
+23% +$174K 0.08% 265
2020
Q4 		$547K Sell
5,240
-3,923
-43% -$397K 0.06% 338
2020
Q3 		$648K Buy
9,163
+537
+6% +$37.4K 0.09% 238
2020
Q2 		$554K Buy
8,626
+5,126
+146% +$281K 0.08% 264
2020
Q1 		$105K Buy
+3,500
New +$80.5K 0.02% 480

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Centaurus Financial's MRNA Position: Q2 2026 in Review

Centaurus Financial held its Moderna (MRNA) position steady in Q2 2026 at 4,477 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #735.

Centaurus Financial first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.81M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Centaurus Financial held 4,477 shares of Moderna worth $314K as of Q2 2026.
  • Centaurus Financial left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.01% of Centaurus Financial's portfolio in Q2 2026, its #735 holding.
  • Centaurus Financial first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Centaurus Financial's Moderna position peaked at $3.81M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.